Pfizer shares drop as Trump appoints Kennedy to health role

Pfizer Inc. shares fell on Thursday after President-elect Donald Trump appointed Robert F. Kennedy Jr. as the next secretary of the Department of Health and Human Services. Kennedy's past criticism of vaccines has raised concerns among investors. Some traders view the stock's decline as a potential buying opportunity, citing the concept of reversion to the mean. Pfizer is currently considered "oversold," which may lead to a price rebound. Additionally, Pfizer's stock has dropped to a previous support level from April. This could encourage investors who sold at that price to buy back in, potentially stabilizing and increasing the stock's value.